Utpal Koppikar
Director/Board Member en C4 THERAPEUTICS, INC. .
Fortuna: 172 592 $ al 31/03/2024
Perfil
Utpal Koppikar is an Independent Director at C4 Therapeutics, Inc. He previously worked as a Director at Flexion Therapeutics, Inc. and as Vice President-Corporate & Operations Finance at Gilead Sciences, Inc. He is also the Chief Financial Officer & Senior Vice President at Atara Biotherapeutics, Inc. Mr. Koppikar holds a graduate degree from Stanford University, an undergraduate degree from the University of Maryland, and an MBA from UCLA Anderson School of Management.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 02/03/2023 | 181 978 ( 0.14% ) | 126 293 $ | 31/03/2024 | |
C4 THERAPEUTICS, INC.
0.01% | 15/06/2023 | 5 667 ( 0.01% ) | 46 299 $ | 31/03/2024 |
Cargos activos de Utpal Koppikar
| Empresas | Cargo | Inicio |
|---|---|---|
| C4 THERAPEUTICS, INC. | Director/Board Member | 16/03/2022 |
Antiguos cargos conocidos de Utpal Koppikar.
| Empresas | Cargo | Fin |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Director of Finance/CFO | 31/03/2023 |
| FLEXION THERAPEUTICS, INC. | Director/Board Member | 19/11/2021 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/06/2018 |
Formación de Utpal Koppikar.
| Stanford University | Graduate Degree |
| University of Maryland | Undergraduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| C4 THERAPEUTICS, INC. | Health Technology |
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Utpal Koppikar
